Asset Details
Do you wish to reserve the book?
Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
Do you wish to request the book?
Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
2025
Overview
Purpose
To evaluate the survival outcomes of huge HCC (tumor size ≥ 10 cm) after surgical resection (SR) with or without neoadjuvant hepatic arterial infusion chemotherapy (HAIC).
Patients and methods
119 huge HCC patients underwent SR in our Hospital (2010–2020). A new HAIC regimen (cisplatin, leucovorin, mitomycin-C and 5-FU infusion for 5 days plus 10 ml lipiodol microvascular embolization) was adopted as the neoadjuvant therapy in 25 patients. Treatment responses were evaluated based on mRECIST criteria. The objective response rate (ORR), disease free survival (DFS), recurrence survival (RS) and overall survival (OS) were compared between the SR-only and neoadjuvant HAIC groups.
Results
Of the 119 patients, 65 patients were Vp2, 9 patients were Vp3 and 4 patients were Vp4. In the subgroup analysis, neoadjuvant HAIC group revealed significantly more severe clinical status. Of the neoadjuvant HAIC patients, ORR was 66.7%. Postoperative tumor recurrence was noted in 75% and 58.3% of the SR and neoadjuvant groups, of them 56.5% and 20.8% developed in ≤ 12 months. The median DFS, RS and OS in each group were 10 vs. 41 months (
p
= 0.016), 36 vs. 91 months and 46 vs. 96 months, respectively. Subgroup analysis revealed no significant survival difference of the RS in both patient groups with tumor recurrence ≤ 12 months (17 vs. 14 months) or > 12 months/without recurrence (not reached vs. 113 months).
Conclusion
Our new regimen HAIC acted as an effective neoadjuvant therapy in reducing early recurrence rate and prolonged DFS of huge HCC after surgical resection.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cancer
/ Carcinoma, Hepatocellular - mortality
/ Carcinoma, Hepatocellular - pathology
/ Carcinoma, Hepatocellular - therapy
/ Cisplatin - administration & dosage
/ Female
/ Fluorouracil - administration & dosage
/ Hepatoma
/ Humans
/ Leucovorin - administration & dosage
/ Liver
/ Male
/ Medicine
/ Mitomycin - administration & dosage
/ Neoadjuvant hepatic arterial infusion chemotherapy
/ Neoadjuvant Therapy - methods
/ Neoadjuvant Therapy - mortality
/ Neoplasm Recurrence, Local - pathology
/ Patients
/ Surgery
/ Survival
/ Tumors
